Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Free Cash Flow (2023 - 2025)

Immunocore Holdings (IMCR) has disclosed Free Cash Flow for 3 consecutive years, with -$36.8 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 101.15% to -$36.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$15.1 million through Dec 2025, down 172.06% year-over-year, with the annual reading at -$15.1 million for FY2025, 172.06% down from the prior year.
  • Free Cash Flow hit -$36.8 million in Q4 2025 for Immunocore Holdings, down from -$4.0 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $25.5 million in Q2 2025 to a low of -$36.8 million in Q4 2025.
  • Historically, Free Cash Flow has averaged $279250.0 across 3 years, with a median of -$606500.0 in 2023.
  • Biggest YoY gain for Free Cash Flow was 1814.15% in 2024; the steepest drop was 166.56% in 2024.
  • Year by year, Free Cash Flow stood at -$18.6 million in 2023, then rose by 1.43% to -$18.3 million in 2024, then tumbled by 101.15% to -$36.8 million in 2025.
  • Business Quant data shows Free Cash Flow for IMCR at -$36.8 million in Q4 2025, -$4.0 million in Q3 2025, and $25.5 million in Q2 2025.